- Investing Ideas
- U.S. Pharmaceuticals & Biotech Potentially Undervalued Small Caps
U.S. Pharmaceuticals & Biotech Potentially Undervalued Small Caps
Results
4
Value score of at least 4 focused on companies with a low market cap.
4 companies
Biofrontera
Market Cap: US$11.5m
A biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
BFRI
US$1.03
7D
29.6%
1Y
54.9%
aTyr Pharma
Market Cap: US$53.6m
A clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States.
ATYR
US$0.52
7D
7.4%
1Y
-90.4%
Grace Therapeutics
Market Cap: US$41.6m
Engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
GRCE
US$2.50
7D
5.9%
1Y
-11.3%
Bioqual
Market Cap: US$29.1m
Provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States.
BIOQ
US$32.50
7D
-7.2%
1Y
n/a